The phosphodiesterase inhibitor cilostazol induces regression of carotid atherosclerosis in subjects with type 2 diabetes mellitus: principal results of the Diabetic Atherosclerosis Prevention by Cilostazol (DAPC) study: a randomized trial (Q38373032)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | The phosphodiesterase inhibitor cilostazol induces regression of carotid atherosclerosis in subjects with type 2 diabetes mellitus: principal results of the Diabetic Atherosclerosis Prevention by Cilostazol (DAPC) study: a randomized trial |
scientific article |
Statements
1 reference
The phosphodiesterase inhibitor cilostazol induces regression of carotid atherosclerosis in subjects with type 2 diabetes mellitus: principal results of the Diabetic Atherosclerosis Prevention by Cilostazol (DAPC) study: a randomized trial (English)
1 reference
Naoto Katakami
1 reference
Young-Seol Kim
1 reference
Ryuzo Kawamori
1 reference
Yoshimitsu Yamasaki
1 reference
1 June 2010
1 reference
1 reference
121
1 reference
23
1 reference
2584-2591
1 reference
Identifiers
1 reference
1 reference